Candriam S.C.A. Has $6.05 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Candriam S.C.A. cut its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 15.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 571,027 shares of the company’s stock after selling 105,217 shares during the quarter. Candriam S.C.A. owned 0.35% of Neumora Therapeutics worth $6,053,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of Neumora Therapeutics by 54.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock valued at $26,159,000 after buying an additional 694,385 shares in the last quarter. Barclays PLC increased its position in Neumora Therapeutics by 352.9% during the 3rd quarter. Barclays PLC now owns 129,210 shares of the company’s stock worth $1,708,000 after purchasing an additional 100,678 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock worth $9,224,000 after purchasing an additional 406,891 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Neumora Therapeutics during the 3rd quarter worth approximately $1,097,000. Finally, Wexford Capital LP increased its position in Neumora Therapeutics by 90.1% during the 3rd quarter. Wexford Capital LP now owns 217,879 shares of the company’s stock worth $2,878,000 after purchasing an additional 103,285 shares in the last quarter. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NMRA has been the subject of a number of research analyst reports. Stifel Nicolaus cut shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $6.00 to $2.00 in a research report on Friday. William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a research report on Wednesday, January 15th. Guggenheim lowered shares of Neumora Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday. Finally, HC Wainwright decreased their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $10.14.

Neumora Therapeutics Price Performance

NMRA opened at $1.49 on Friday. The company’s 50-day moving average is $2.44 and its 200 day moving average is $8.64. Neumora Therapeutics, Inc. has a fifty-two week low of $1.30 and a fifty-two week high of $21.00. The firm has a market capitalization of $240.73 million, a P/E ratio of -0.80 and a beta of 2.59.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. On average, equities research analysts expect that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.